-
Sector Analysis
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
Methicillin-Resistant Staphylococcus aureus (MRSA) Report Overview In the 7MM, there were 714,131 hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) in 2023. The hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) will register an AGR of more than 1% during 2023-2033. Methicillin-resistant Staphylococcus aureus (MRSA) is a virulent, antibiotic-resistant bacteria that is associated with considerable morbidity and mortality. MRSA can be categorized according to the setting in which the infection was acquired, as either healthcare-associated MRSA (HA-MRSA), which is acquired...
-
Product Insights
Likelihood of Approval Analysis for Gram-Positive Bacterial Infections
Overview How likely is it that the drugs in Gram-Positive Bacterial Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gram-Positive Bacterial Infections Overview Gram-positive bacterial infections are caused by bacteria...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalbavancin in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalbavancin in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalbavancin in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Metastatic Prostate Cancer Drug Details: Spartalizumab (PDR-001) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tebipenem Pivoxil Hydrobromide in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tebipenem Pivoxil Hydrobromide in Urinary Tract Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tebipenem Pivoxil Hydrobromide in Urinary Tract Infections Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tebipenem Pivoxil Hydrobromide in Pyelonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tebipenem Pivoxil Hydrobromide in Pyelonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tebipenem Pivoxil Hydrobromide in Pyelonephritis Drug Details: Tebipenem pivoxil hydrobromide (Orapenem)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MV-130 in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MV-130 in Urinary Tract Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MV-130 in Urinary Tract Infections Drug Details: MV-130 (Bactek) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Delpazolid in Mycobacterium Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delpazolid in Mycobacterium Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delpazolid in Mycobacterium Infections Drug Details: Delpazolid (LCB-010371) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R-327 in Influenza A Virus, H1N1 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-327 in Influenza A Virus, H1N1 Subtype Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-327 in Influenza A Virus, H1N1 Subtype...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – R-327 in Bacterial Sepsis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - R-327 in Bacterial Sepsis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. R-327 in Bacterial Sepsis Drug Details: R-327 is under development for the...